Allarity Therapeutics, Inc. has reported a significant change in its executive management structure through a filing with the SEC. The company, based in Delaware and listed under the ticker ALLR on the Nasdaq Stock Market, disclosed the replacement of a consultancy agreement with a new Management Services Agreement (MSA) with Ljungaskog Consulting AB, effective June 1, 2024. This new agreement engages Thomas H. Jensen, the CEO of Allarity Therapeutics, to continue his services with a fixed monthly fee of $43,750 and a one-time signing bonus of $100,000. The MSA outlines performance-based compensation adjustments, eligibility for annual discretionary performance bonuses, and expense reimbursements. It also details termination provisions for both the company and the consultant, including termination for convenience and for cause, with specific financial implications. The MSA supersedes the previous consultancy agreement and is set to continue until the agreed termination conditions are met. The full text of the MSA is included as Exhibit 10.1 in the SEC filing.

Allarity Therapeutics, Inc. has reported a significant change in its executive management structure through a filing with the SEC. The company, based in Delaware and listed under the ticker ALLR on the Nasdaq Stock Market, disclosed the replacement of a consultancy agreement with a new Management Services Agreement (MSA) with Ljungaskog Consulting AB, effective June 1, 2024. This new agreement engages Thomas H. Jensen, the CEO of Allarity Therapeutics, to continue his services with a fixed monthly fee of $43,750 and a one-time signing bonus of $100,000. The MSA outlines performance-based compensation adjustments, eligibility for annual discretionary performance bonuses, and expense reimbursements. It also details termination provisions for both the company and the consultant, including termination for convenience and for cause, with specific financial implications. The MSA supersedes the previous consultancy agreement and is set to continue until the agreed termination conditions are met. The full text of the MSA is included as Exhibit 10.1 in the SEC filing.